These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

631 related articles for article (PubMed ID: 35703177)

  • 1. Circulating tumor DNA: current challenges for clinical utility.
    Dang DK; Park BH
    J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35703177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
    Shields MD; Chen K; Dutcher G; Patel I; Pellini B
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unlocking the future of cancer diagnosis - promises and challenges of ctDNA-based liquid biopsies in non-small cell lung cancer.
    Reina C; Šabanović B; Lazzari C; Gregorc V; Heeschen C
    Transl Res; 2024 Oct; 272():41-53. PubMed ID: 38838851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
    Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
    Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of Minimal Residual Disease Using ctDNA in Lung Cancer: Current Evidence and Future Directions.
    Chae YK; Oh MS
    J Thorac Oncol; 2019 Jan; 14(1):16-24. PubMed ID: 30296486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal ctDNA profiling in precision oncology and immunο-oncology.
    Filis P; Kyrochristos I; Korakaki E; Baltagiannis EG; Thanos D; Roukos DH
    Drug Discov Today; 2023 Apr; 28(4):103540. PubMed ID: 36822363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How liquid biopsies can change clinical practice in oncology.
    Siravegna G; Mussolin B; Venesio T; Marsoni S; Seoane J; Dive C; Papadopoulos N; Kopetz S; Corcoran RB; Siu LL; Bardelli A
    Ann Oncol; 2019 Oct; 30(10):1580-1590. PubMed ID: 31373349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating tumor DNA in early-stage breast cancer: new directions and potential clinical applications.
    Croessmann S; Park BH
    Clin Adv Hematol Oncol; 2021 Mar; 19(3):155-161. PubMed ID: 33739964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer.
    Arisi MF; Dotan E; Fernandez SV
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Commercial ctDNA Assays for Minimal Residual Disease Detection of Solid Tumors.
    Chen K; Shields MD; Chauhan PS; Ramirez RJ; Harris PK; Reimers MA; Zevallos JP; Davis AA; Pellini B; Chaudhuri AA
    Mol Diagn Ther; 2021 Nov; 25(6):757-774. PubMed ID: 34725800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toward liquid biopsies in cancer treatment: application of circulating tumor DNA.
    Barlebo Ahlborn L; Østrup O
    APMIS; 2019 May; 127(5):329-336. PubMed ID: 30784124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liquid biopsy in lymphoma: Molecular methods and clinical applications.
    Cirillo M; Craig AFM; Borchmann S; Kurtz DM
    Cancer Treat Rev; 2020 Dec; 91():102106. PubMed ID: 33049623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Profiling of Liquid Biopsies for Precision Oncology.
    Gonzalez-Kozlova EE
    Adv Exp Med Biol; 2022; 1361():235-247. PubMed ID: 35230692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group.
    Pascual J; Attard G; Bidard FC; Curigliano G; De Mattos-Arruda L; Diehn M; Italiano A; Lindberg J; Merker JD; Montagut C; Normanno N; Pantel K; Pentheroudakis G; Popat S; Reis-Filho JS; Tie J; Seoane J; Tarazona N; Yoshino T; Turner NC
    Ann Oncol; 2022 Aug; 33(8):750-768. PubMed ID: 35809752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer.
    Nakamura Y; Yoshino T
    Oncologist; 2018 Nov; 23(11):1310-1318. PubMed ID: 29700206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ultrasensitive circulating tumor DNA analysis enables precision medicine: experimental workflow considerations.
    Andersson D; Kristiansson H; Kubista M; Ståhlberg A
    Expert Rev Mol Diagn; 2021 Mar; 21(3):299-310. PubMed ID: 33683971
    [No Abstract]   [Full Text] [Related]  

  • 17. The breast is yet to come: current and future utility of circulating tumour DNA in breast cancer.
    Davidson BA; Croessmann S; Park BH
    Br J Cancer; 2021 Sep; 125(6):780-788. PubMed ID: 34040179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging Roles of Circulating Tumor DNA for Increased Precision and Personalization in Radiation Oncology.
    Earland N; Chen K; Semenkovich NP; Chauhan PS; Zevallos JP; Chaudhuri AA
    Semin Radiat Oncol; 2023 Jul; 33(3):262-278. PubMed ID: 37331781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.
    Cheng F; Su L; Qian C
    Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current status of ctDNA in precision oncology for hepatocellular carcinoma.
    Li Y; Zheng Y; Wu L; Li J; Ji J; Yu Q; Dai W; Feng J; Wu J; Guo C
    J Exp Clin Cancer Res; 2021 Apr; 40(1):140. PubMed ID: 33902698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.